COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff. Learn more about guidelines for the resumption of live
(in-person) courses and conferences
effective July 1, 2021 and available COVID-19 online education and resources.
Karyopharm Therapeutics - Exhibitor


Company Website

Contact information

Marilee McGraw
mmcgraw@karyopharm.com
612-618-8510

Rebecca Bean, MSN, RN, OC
rbean@karyopharm.com 
914-260-8741

Click on the link to connect with a LIVE representative: https://karyopharm.zoom.us/j/91647012656?pwd=SWJMa0IvR3NCUGNmQ0xQTzZnWmVUZz09

Virtual Exhibit Hall Home

Karyopharm Therapeutics is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets in cancer. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers. US-NON-08/18-00002 (3/2020)

Additional Information:

Prescribing Information

Learn About Our New Indication

Patient Profiles